We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Preoperative Oral Carbohydrate Drink for Elective Cesarean Delivery and the Effect on Insulin Sensitivity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03494868
Recruitment Status : Suspended (need additional funding)
First Posted : April 11, 2018
Last Update Posted : April 6, 2022
Information provided by (Responsible Party):
Emily E. Sharpe, M.D., Mayo Clinic

Brief Summary:
Preoperative fasting and surgery can cause metabolic stress and insulin resistance. Oral carbohydrate loading has been shown to attenuate the development of insulin resistance in the non-pregnant population undergoing many different types of surgery. Pregnant women have an increase in insulin resistance and therefore may further benefit from a preoperative carbohydrate load prior to cesarean delivery. Although woman in the UK receive a carbohydrate drink prior to elective cesarean delivery, the metabolic effects of these drinks on the mother and neonate have not been evaluated.

Condition or disease Intervention/treatment Phase
Insulin Sensitivity Dietary Supplement: Carbohydrate Drink Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 75 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Preoperative Oral Carbohydrate Drink for Elective Cesarean Delivery and the Effect on Insulin Sensitivity
Actual Study Start Date : March 13, 2019
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: Fasting
Fasting prior to elective cesarean section delivery (standard of care)
Experimental: Carbohydrate Drink
Subjects will drink 2 carbohydrate drinks prior to elective cesarean section delivery
Dietary Supplement: Carbohydrate Drink
2 - 12 oz drinks
Other Name: Clearfast Preop Drink

Primary Outcome Measures :
  1. Oral glucose tolerance test [ Time Frame: 24 hours postoperatively ]
    glucose, insulin

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   0 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes


  • ASA physical status II-III women presenting for scheduled, elective cesarean delivery under neuraxial anesthesia
  • Singleton gestation at term (37-42 weeks)
  • Ages 18-50


  • Preexisting diabetes (Gestational diabetes, Type I DM, Type II DM)
  • Taking insulin-sensitizing or other medications known to influence glucose or fatty acid metabolism.
  • Kidney, heart, or liver disease. Severe lipid disorders.
  • History of bariatric surgery
  • Pre-pregnancy BMI >40
  • Prolonged period of time (>4 hours) between ingestion of carbohydrate drink and surgery
  • Four or more repeat cesarean sections

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03494868

Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Emily E Sharpe, MD Mayo Clinic
Additional Information:
Layout table for additonal information
Responsible Party: Emily E. Sharpe, M.D., Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier: NCT03494868    
Other Study ID Numbers: 16-009567
First Posted: April 11, 2018    Key Record Dates
Last Update Posted: April 6, 2022
Last Verified: April 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin Resistance
Immune System Diseases
Glucose Metabolism Disorders
Metabolic Diseases